BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Almirall readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Almirall's drugs run\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06526182-1423@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT06526182)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3\, Atopic Dermatitis.\nStudy: A
  Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-t
 o-Severe Atopic Dermatitis\nEstimated primary completion: 25 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/lebrikizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06526182
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06338995-1423@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT06338995)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3.\nStudy: A Study of Lebrikizum
 ab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyp
 s Treated With Intranasal Corticosteroids (CONTRAST-NP)\nEstimated primary
  completion: May 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/lebrikizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06338995
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05735483-1423@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT05735483)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3\, Atopic Dermatitis.\nStudy: A
  Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650
 150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe 
 Atopic Dermatitis\nEstimated primary completion: December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lebrikizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05735483
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07873801-1423@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT07873801)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3\, Atopic Dermatitis.\nStudy: A
  Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic
  Dermatitis\nEstimated primary completion: February 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lebrikizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07873801
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07542483-1423@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ebglyss (lebrikizumab): Phase 3 readout est. (NCT07542483)
DESCRIPTION:Ebglyss (lebrikizumab)\, phase 3.\nStudy: A Study of Lebrikizum
 ab in Adults With Nummular Eczema\nEstimated primary completion: August 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lebrikizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07542483
URL:https://assetmemo.bio/drug/lebrikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04991116-99@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ilumya (tildrakizumab): Phase 3 readout est. (NCT04991116)
DESCRIPTION:Ilumya (tildrakizumab)\, phase 3\, Psoriatic Arthritis.\nStudy:
  Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients 
 With Psoriatic Arthritis\nEstimated primary completion: December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tildrakizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04991116
URL:https://assetmemo.bio/drug/tildrakizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
